TANGO THERAPEUTICS INC (TNGX) Stock Price, Quote, News and Overview
NASDAQ:TNGX - Nasdaq - US87583X1090 - Common Stock - Currency: USD
TNGX Quote, Performance and Key Statistics
1.46
0 (0%)
The current stock price of TNGX is 1.46 USD. In the past month the price decreased by -9.32%. In the past year, price decreased by -80.38%.
TNGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About TNGX
Company Profile
Tango Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in discovering and delivering precision cancer medicines. The company is headquartered in Boston, Massachusetts and currently employs 155 full-time employees. The company went IPO on 2020-09-03. The firm leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The firm's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Company Info
TANGO THERAPEUTICS INC
201 Brookline Avenue, Suite 901
Boston MASSACHUSETTS US
CEO: Aaron I. Davis
Employees: 155
Company Website: https://www.tangotx.com/
Investor Relations: https://ir.tangotx.com/
Phone: 18573204900
TANGO THERAPEUTICS INC / TNGX FAQ
What is the stock price of TANGO THERAPEUTICS INC today?
The current stock price of TNGX is 1.46 USD.
What is the ticker symbol for TANGO THERAPEUTICS INC stock?
The exchange symbol of TANGO THERAPEUTICS INC is TNGX and it is listed on the Nasdaq exchange.
On which exchange is TNGX stock listed?
TNGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TANGO THERAPEUTICS INC stock?
14 analysts have analysed TNGX and the average price target is 11.22 USD. This implies a price increase of 668.49% is expected in the next year compared to the current price of 1.46. Check the TANGO THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TANGO THERAPEUTICS INC worth?
TANGO THERAPEUTICS INC (TNGX) has a market capitalization of 157.84M USD. This makes TNGX a Micro Cap stock.
How many employees does TANGO THERAPEUTICS INC have?
TANGO THERAPEUTICS INC (TNGX) currently has 155 employees.
What are the support and resistance levels for TANGO THERAPEUTICS INC (TNGX) stock?
TANGO THERAPEUTICS INC (TNGX) has a support level at 1.36 and a resistance level at 1.5. Check the full technical report for a detailed analysis of TNGX support and resistance levels.
Is TANGO THERAPEUTICS INC (TNGX) expected to grow?
The Revenue of TANGO THERAPEUTICS INC (TNGX) is expected to decline by -34.17% in the next year. Check the estimates tab for more information on the TNGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy TANGO THERAPEUTICS INC (TNGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TNGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TNGX, evaluating the profitability, health, valuation and growth aspects
- TANGO THERAPEUTICS INC (TNGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TANGO THERAPEUTICS INC (TNGX) Sales and EPS estimates to see what analysts future expectations are.
- TANGO THERAPEUTICS INC (TNGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TANGO THERAPEUTICS INC (TNGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- TANGO THERAPEUTICS INC (TNGX) Stock Chart to make your own analysis
- TANGO THERAPEUTICS INC (TNGX) Latest news and press-releases to stay up to date.
Does TANGO THERAPEUTICS INC (TNGX) stock pay dividends?
TNGX does not pay a dividend.
When does TANGO THERAPEUTICS INC (TNGX) report earnings?
TANGO THERAPEUTICS INC (TNGX) will report earnings on 2025-05-07, before the market open.
What is the Price/Earnings (PE) ratio of TANGO THERAPEUTICS INC (TNGX)?
TANGO THERAPEUTICS INC (TNGX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.21).
What is the Short Interest ratio of TANGO THERAPEUTICS INC (TNGX) stock?
The outstanding short interest for TANGO THERAPEUTICS INC (TNGX) is 9.26% of its float. Check the ownership tab for more information on the TNGX short interest.
TNGX Technical Analysis
TNGX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TNGX. No worries on liquidiy or solvency for TNGX as it has an excellent financial health rating, but there are worries on the profitability.
TNGX Financial Highlights
Over the last trailing twelve months TNGX reported a non-GAAP Earnings per Share(EPS) of -1.21. The EPS decreased by -10% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.17% | ||
| ROE | -65.31% | ||
| Debt/Equity | 0 |
TNGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 87% to TNGX. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of -17.38% and a revenue growth -34.17% for TNGX